Abstract
The heterodimeric transcription factor HIF-1 (hypoxia-inducible factor-1) induces angiogenesis, a process that is aberrantly elevated in cancer. The HIF-1β subunit is constitutively expressed, but the levels of the HIF-1α subunit are robustly regulated, increasing under hypoxic conditions and decreasing in normoxia. These changes result from rapid alterations in the rates of HIF-1α production and degradation. While the regulation of HIF-1α degradation is understood in significant detail, much less is known about the regulation of HIF-1α biosynthesis. Here, we review recent evidence that HIF-1α production is effectively controlled by post-transcriptional mechanisms. We focus on the RNA-binding proteins (RBPs) and the non-coding RNAs that interact with the HIF-1α mRNA and influence its half-life and translation rate. HIF-1α mRNA-binding factors are emerging as promising pharmacological targets to control HIF-1α production selectively and efficiently.
Keywords: Post-transcriptional gene regulation, RNA-binding proteins, microRNA, antisense RNA, IRES
Current Pharmaceutical Design
Title: Factors Interacting with HIF-1α mRNA: Novel Therapeutic Targets
Volume: 15 Issue: 33
Author(s): Stefanie Galban and Myriam Gorospe
Affiliation:
Keywords: Post-transcriptional gene regulation, RNA-binding proteins, microRNA, antisense RNA, IRES
Abstract: The heterodimeric transcription factor HIF-1 (hypoxia-inducible factor-1) induces angiogenesis, a process that is aberrantly elevated in cancer. The HIF-1β subunit is constitutively expressed, but the levels of the HIF-1α subunit are robustly regulated, increasing under hypoxic conditions and decreasing in normoxia. These changes result from rapid alterations in the rates of HIF-1α production and degradation. While the regulation of HIF-1α degradation is understood in significant detail, much less is known about the regulation of HIF-1α biosynthesis. Here, we review recent evidence that HIF-1α production is effectively controlled by post-transcriptional mechanisms. We focus on the RNA-binding proteins (RBPs) and the non-coding RNAs that interact with the HIF-1α mRNA and influence its half-life and translation rate. HIF-1α mRNA-binding factors are emerging as promising pharmacological targets to control HIF-1α production selectively and efficiently.
Export Options
About this article
Cite this article as:
Galban Stefanie and Gorospe Myriam, Factors Interacting with HIF-1α mRNA: Novel Therapeutic Targets, Current Pharmaceutical Design 2009; 15 (33) . https://dx.doi.org/10.2174/138161209789649376
DOI https://dx.doi.org/10.2174/138161209789649376 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy
Current Cancer Drug Targets Nanotechnology and Brain Tumors Drug Delivery
Recent Patents on Nanomedicine Antibody Engineering, Virus Retargeting and Cellular Immunotherapy: One Ring to Rule Them All?
Current Gene Therapy Editorial :
Recent Patents on CNS Drug Discovery (Discontinued) A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response
Current Gene Therapy Raman Spectroscopy and Imaging: Promising Optical Diagnostic Tools in Pediatrics
Current Medicinal Chemistry Preservation of Cellular Glutathione Status and Mitochondrial Membrane Potential by N-Acetylcysteine and Insulin Sensitizers Prevent Carbonyl Stress-Induced Human Brain Endothelial Cell Apoptosis
Current Neurovascular Research Multi-Modality Discrimination of Brain Glioma Grades Using Diffusion Tensor and Spectroscopic MRI
Recent Patents on Medical Imaging Applications of Computed Tomography, Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy for Planning External Beam Radiotherapy
Current Medical Imaging Therapeutic Potential of Curcumin in the Treatment of Glioblastoma Multiforme
Current Pharmaceutical Design Methods of Preparation of Multifunctional Microbubbles and their In Vitro / In Vivo Assessment of Stability, Functional and Structural Properties
Current Pharmaceutical Design Targeting Death Receptors to Fight Cancer: From Biological Rational to Clinical Implementation
Current Medicinal Chemistry Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Superparamagnetic Magnetite (Fe3O4) Nanoparticles for Bio-Applications
Recent Patents on Materials Science The Cyclin-Dependent Kinase Inhibitor p21CDKN1A as a Target of Anti-Cancer Drugs
Current Cancer Drug Targets New Insights Toward Nanostructured Drug Delivery of Plant-Derived Polyphenol Compounds: Cancer Treatment and Gene Expression Profiles
Current Cancer Drug Targets Role of Progastrins and Gastrins and Their Receptors in GI and Pancreatic Cancers: Targets for Treatment
Current Pharmaceutical Design Functions of S100 Proteins
Current Molecular Medicine PLGA Hollow Microbubbles Loaded with Iron Oxide Nanoparticles and Doxorubicin for Dual-mode US/MR Imaging and Drug Delivery
Current Nanoscience Alpha-Particle Microdosimetry
Current Radiopharmaceuticals